How the MHRA processes variations to marketing authorisations.
Similar Posts
MHRA approves zapomeran (Kostaive) mRNA COVID-19 vaccine
As with any medicine, the MHRA will keep the safety and effectiveness of zapomeran under close review.
Decision: Marketing authorisations granted in 2025
Marketing authorisations granted in 2025.
Field Safety Notices: 11 to 15 August 2025
List of Field Safety Notices from 11 to 15 August 2025.
MHRA Safety Roundup: May 2025
Summary of the latest safety advice for medicines and medical device users
If you take a GLP-1 medicine and have been hospitalised by acute pancreatitis, the Yellow Card Biobank wants to hear from you
GLP-1 medicines are licensed for Type 2 diabetes and weight management, and include the branded products Ozempic, Mounjaro and Wegovy
Class 2 Medicines Recall: Inhixa 12,000IU (120mg)/0.8mL solution for injection, Maxearn Limited, EL(25)A/27
Maxearn Limited have informed the MHRA that the carton used to package two imported batches of Inhixa have been released to the market with a typographical error on one side of the carton.